2nd Annual National Opioid Crisis Management Congress
September 27-28, 2018 * Omni Shoreham Hotel * Washington, DC

2nd Annual National Opioid Crisis Management Congress

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

About the Conference

National attention is focused on the opioid crisis, and communities are struggling to respond. According to the U.S. Centers for Disease Control, as the clinical use of opioids has risen over the past two decades, opioid-associated harm has risen in parallel.

Chronic pain affects approximately 100 million Americans, making it one of the most common reasons for patients to seek medical care. Over the past decade, there has been a four-fold increase in opioid prescribing. During the same time period, there was a four-fold increase in unintentional opioid overdose deaths and a five-fold increase in substance abuse treatment admissions for prescription opioid addiction.

The ongoing opioid crisis lies at the intersection of two substantial public health challenges—reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications.

This conference will address the state of the science in pain management, characterize the epidemiology of the opioid epidemic, and identify actions that can be taken to respond to this crisis. Gain expert insight into an epidemic from top thought leaders in opioid management who will share their latest research and real-world knowledge in the evolving paradigm of opioids in medicine. In addition, experts at the state and federal levels providing leadership on the opioid public health crisis will present developing collaborative strategic partnerships to serve our most vulnerable citizens.

Who Should Attend?
From Hospitals/Health Systems/Health Plans/Gov’t Agencies/Law Enforcement

  • CEO
  • CFO
  • VP
  • Medical Directors
  • Behavioral Health Directors
  • Pharmacy Directors
  • Clinical Pharmacists
  • Social Workers
  • Outreach Coordinators
  • PDMP Directors
  • Pain Management Directors
  • Psychiatrists
  • Psychologists
  • Telehealth Directors
  • State Health Directors
  • Nursing Director
  • Emergency Room Directors
  • Substance Abuse & Prevention Directors
  • Pediatricians
  • Law Enforcement
  • Narcotic Enforcement
  • Physicians
  • Quality Improvement Director
  • Family Services Director
  • Clinical Directors
  • Investigators
  • Compliance Director
  • Correctional Coordinators

This Event Will Also be if Interest to:

  • Pharmaceutical Companies * Law Firms * Consultants * Drug Development Companies

Conference Agenda

Day One – Thursday, September 27, 2018
7:15am – 8:00am
Conference Registration & Networking Breakfast

8:00am – 8:15am
Chair’s Opening Remarks

8:15am – 9:00am
Keynote: FDA Actions to Confront the Opioid Crisis
A call for informed professionals to engage in a discussion of timely opioid-related policy matters, this session will discuss some of the activities the FDA is undertaking to confront the opioid crisis in the United States. Included in the discussion will be the framework FDA is using to focus its efforts as well as ongoing or planned activities by the Agency in this critical public health area. Topics will include:
– The role of the FDA in improving the assessment and treatment of pain in the patient and in identifying patients at risk for prescription opioid abuse
– The work FDA is doing to assess the real-world efficacy of abuse-deterrent opioids
– The work FDA is doing to reduce the numbers of prescription opioids available for potential diversion and abuse by reducing the prescription size and by improving drug disposal

Douglas Throckmorton, MD
Deputy Center Director of Regulatory Programs
U.S. Food and Drug Administration (FDA)

9:00am – 9:45am
Community Solutions to the Opioid Epidemic: Advancing Provider Education and Collaborating with All Stakeholders
Opioid addiction is a community-wide issue that requires a community-wide response. Every day, clinicians see firsthand the devastating effects of the opioid epidemic on patients, families and communities. How clinicians provide care to patients who are opioid-dependent or have overdosed, how they think about and prescribe opioids, how they connect patients to treatment resources, and how well they are collaborating with other stakeholders are all key to better treatment, results and recovery. Preventing opioid overdose requires collaboration with a diverse range of partners. Partnerships between hospitals, community organizations, and law enforcement have been effective in expanding access to naloxone, coordinating treatment and care and saving lives. Topics to be discussed will include:
– How prevention practitioners can create a framework to address the multiple systems within communities
– How to identify potential partners whose involvement is critical to preventing opioid overdose
– Challenges prevention practitioners may face collaborating with the medical community to prevent prescription drug misuse
– Strategies for building these important partnerships

Deena Speights-Napata, MA
Executive Director
Maryland Board of Pharmacy
Maryland Department of Health

9:45am – 10:15am
Networking Break

10:15am – 11:00am
The Opioid and Heroin Epidemic: A Personal Story
Robin will share her personal story as a mother of her 25-year-old son who was a victim of the opioid and heroin epidemic, illustrating the devastating effects of the disease of addition on families, marriages, sibling relationships, friends and community members of the addict. She has been a psychotherapist and substance abuse counselor for nearly 30 years years and yet could not save my son after his 8-year battle with opioid and heroin addiction. When this battle ended in her son’s death in December 2016, the loss of him in all of the concentric circles of his relationships was unimaginable, yet tragically becoming all too commonplace in the U.S.

Robin Monson-Dupuis, LCSW, SAC, RYT
Director, Aurora Behavioral Health Services
Aurora Medical Group

11:00am – 11:45am
Lessons Learned: How Michigan Transformed its PMP, What worked? What did not? What were the results?
On April 4, 2017, Michigan fully replaced and launched a new prescription monitoring program (PMP). This system replacement was one of the most successful IT projects in the state of Michigan’s history. How did Michigan make this happen? What lessons were learned? What were the challenges? Results? Join this session to learn how Michigan is positioning to try to get ahead of the opioid epidemic with innovative technologies and best practices including: (1) Deploying a highly scalable PDMP platform capable of handling increased demand, (2) Facilitating integration of multistate PDMP data and analytics within EHR and pharmacy workflow, (3) Deployment of clinical tools to help clinicians engage further with their patients to include warm-handoff treatment options and (4) Deploying advanced analytics, machine learning technology and AI to detect patients at an increased risk of an overdose event and movement towards illicit drug events. This is just the beginning as more enhancements and possibilities are being implemented and considered. With a little creativity and innovative thinking, anything is possible. Overall the efficiencies established with this new system have helped Michigan to dedicate its resources in a more appropriate and impactful manner. Areas such as education and outreach, data analytics, and improving its regulatory efforts with a more robust approach were unattainable with its older, home-grown program. But, if you fast forward to today, Michigan has not only completed these items, but it continues to do more.

Kim Gaedeke
Acting Deputy Director
Department of Licensing and Regulatory Affairs
State of Michigan

11:45am – 1:00pm
Lunch

1:00pm – 1:45pm
Reducing Opioid Prescribing Rates in Emergency Medicine
Pain management is one of the most common reasons patients visit the emergency department. This session will address the importance of understanding the contributions of emergency medicine to the opioid crisis and how one might construct a simple but elegant and efficient approach to reduce opioid prescription rates amongst emergency physicians. Importantly the speaker will demonstrate the methodology for this approach including the issues surrounding the practice of physician performance data transparency. The results will be discussed demonstrating a dramatic decrease in opioid prescription rates. Finally, interesting data related to the impact on patient satisfaction will be addressed.

Joe Guarisco, MD, FAAEM, FACEP
System Chair Emergency Services
Academic Chair Department of Emergency Medicine
Ochsner Health System

1:45pm – 2:30pm
The Overdose Detection Mapping Application Program (ODMAP): A Data-Driven Strategy to Track and Respond to Overdoses
ODMAP, a web-based tool created by the Washington/Baltimore High Intensity Drug Trafficking Areas (W/B HIDTA), provides real-time overdose surveillance data to public health and safety partners. The system links first responders on scene to a mapping tool to track overdoses to stimulate real-time response and strategic analysis across jurisdictions. In this session we will provide an overview of the nation’s drug threat and the need for enhanced data sharing and collaboration. We will discuss how ODMAP is being used through 30 states nationally, highlighting best practices and successful strategies in addressing the overdose epidemic.

Jeff Beeson
Deputy Director
Washington/Baltimore High Intensity Drug Trafficking Areas

2:30pm – 3:00pm
Networking Break

3:00pm – 4:15pm
Panel: Prescription Drug Monitoring Program Perspectives
Prescription drug monitoring programs (PDMPs) continue to be among the most promising state-level interventions to improve opioid prescribing, inform clinical practice and protect patients at risk. Although findings are mixed, evaluations of PDMPs have illustrated changes in prescribing behaviors, use of multiple providers by patients, and decreased substance abuse treatment admissions. States have implemented a range of ways to make PDMPs easier to use and access, and these changes have significant potential for ensuring that the utility and promise of PDMPs are realized. This panel will feature PDMPs leaders from various states that will discuss the following topics:
– Supporting access to legitimate medical use of controlled substances
– How to identify and deter or prevent drug abuse and diversion
– Facilitating and encouraging the identification, intervention with and treatment of persons addicted to prescription drugs
– Informing public health initiatives through outlining of use and abuse trends
– Educating individuals about PDMPs and the use, abuse and diversion of and addiction to prescription drugs

Moderator:
Brad Bauer
Senior Vice President, Business Development
Appriss Health

Panelists:
Andrew Funk, PharmD
Executive Director
Iowa Board of Pharmacy

Erika L. Marshall
Program Outreach Director
E-FORCSE Florida Prescription Drug Monitoring Program

Cody Wiberg, PharmD, MS, RPh
Executive Director
Minnesota Board of Pharmacy

4:15pm – 5:00pm
New Law Enforcement Tools and Resources to Address the Opioid Crisis
This session will address new initiatives to take action to make drug enforcement efforts more effective. Topics to be discussed will include:
– Grant funding to assist law enforcement in combatting illegal manufacturing and distribution of opioids
– Resources to better align law enforcement efforts with the community
– Resources to better coordinate and optimize opioid prosecutions
– Improving operations and interagency cooperation and more efficiently leveraging resources
– More effective investigations

Alan McGill
Supervisory Narcotics Agent
Pennsylvania Office of Attorney General, Bureau of Narcotics Investigation and Drug Control

5:00pm
End of Day One

Day Two, Friday, September 28, 2018

7:15am – 8:00am
Networking Breakfast

 

8:00am – 8:15am
Chair’s Recap

 

8:15am – 9:00am
Prescription Opioid Abuse: Challenges and Opportunities for Insurers
Insurance companies are taking measures to combat the staggering opioid addiction numbers and deaths. Prescription opioid abuse and addiction are serious problems with growing societal and medical costs, resulting in billions of dollars of excess costs to health insurers annually. The cost to public and private insurance companies of prescription painkiller abuse, treatment and diversion is an estimated $72.5 billion a year. This session will address payer strategies to control these costs and mitigate financial risks, while supporting safe use of prescription opioid medications for patients with chronic pain.

 

Jody Gembarski, PharmD
Clinical Manager, Pharmacy Services
Clinical Quality Programs and Controlled Substances
Blue Cross Blue Shield of Michigan and Blue Care Network

 

9:00am – 9:45am
 Opioid and other Drug Overdoses among Women
Drug-related overdose deaths surpassed motor vehicle crash-related deaths as the leading cause of injury death among women in 2007. Overdoses continue to be a serious and growing problem among women. On average, approximately 60 women died every day in 2016 from a drug overdose. In this complex and rapidly evolving epidemic it is important to capture current trends and understand how the epidemic is progressing among specific groups in the United States. In particular, consideration of the unique aspects of women’s lives, across factors such as age, race, and geography are crucial. Curbing the epidemic will require the collective efforts of public health practitioners, medical personnel, emergency departments, first responders, public safety officials, mental health and substance abuse treatment providers, and community-based organizations. Topics will include:
– Drug overdose trends among women
– Extent of the overdose epidemic among women nationally and by state
– Consideration of the intersection of gender and drug use

 

Karin A. Mack, PhD
Associate Director for Science
Division of Analysis, Research and Practice Integration
National Center for Injury Prevention and Control
Centers for Disease Control and Prevention (CDC)

 

9:45am – 10:30am
Considerations When Implementing Medication-Assisted Treatment for Opioid Dependent Patients

 

Brian Caveney, M.D.
Chief Medical Officer
LabCorp

 

10:30am – 11:00am

 

Networking Break

 

11:00am – 11:45am
Behavioral Health: Increasing Access to Care Treatment and Services
Behavioral health is an important means to unite the diverse components of an individual’s care in order to ensure that care, treatment and services provided are accessible, family-centered, continuous, comprehensive, coordinated, compassionate and culturally effective. With the advent of healthcare reform, an increasing number of behavioral healthcare organizations have sought to offer integrated primary healthcare for the individuals and families that they serve. This session will discuss the decision-making process for behavioral healthcare organizations considering offering integrated care, with a focus on how the provision of medication assisted treatment is included in that process.

 

Susan Hawk, MS, PCC-S, LSW, CGP
Chief Clinical Integration Behavioral Health
Mercy Health
Director of Operations Behavioral Health
St. Rita’s Health Partners

11:45am – 12:30pm
How to Build a Health-System Wide Opioid Stewardship Program
As the opioid crisis worsens, patients, families and communities are looking to hospitals and health systems to create meaningful solutions. The hospital is the epicenter of the issue, treating acute pain in the ED and after surgery, managing chronic pain, and providing care for patients with substance use disorder. Addressing this broad spectrum of issues can be optimized by creating an “Opioid Stewardship Program,” a comprehensive, multidisciplinary, hospital or health system-wide intervention. In this talk, we’ll discuss the current needs of hospitals and how a program can be structured, focusing on addressing prescribing of opioids, treating patients with substance use disorder, and providing staff education. Participants will learn a framework and several ideas that they can hopefully bring back to their own institutions.

 

Scott Weiner, MD
Attending Emergency Physician
Director, Brigham Comprehensive Opioid Response and Education (B-CORE) Program
Brigham and Women’s Hospital

12:30pm
Conference Concludes

 

Workshop – Friday, September 28, 2018
12:45pm – 2:45pm
How Medication-Assisted Treatment Can Improves Outcomes for Patients With Opioid Use Disorder
Medication-assisted treatment (MAT) is an effective response to opioid use disorder and can be a life-saving and cost-saving intervention. It is the use of medications, in combination with behavioral therapies, to provide a whole-patient approach to the treatment of substance use disorders. Individuals receiving MAT often demonstrate dramatic improvement in addiction-related behaviors and psychosocial functioning. MAT is proven to significantly reduce illicit opioid use compared with nondrug approaches, and increased access to these therapies can reduce overdose fatalities. However, MAT is often unavailable to those in need of it because of inadequate funding for treatment programs and a lack of qualified providers who can deliver these therapies. This workshop will address various types of approved medications, screening and assessment tools, and best practices for patient care.

Jake Nichols, PharmD, MBA
Chief Executive Officer
Strategic Recovery Resources, LLC

Jake Nichols is a pharmacist in long‐term recovery with extensive experience in community pharmacy, academia, primary care, managed care, and pharmaceutical industry. He specializes in the treatment of substances use disorders, with a focus on medication-assisted treatment. Through his fifteen‐year struggle with substance abuse, he found his calling in the field and has dedicated his career to helping patients and their families suffering from this debilitating chronic disease. By providing clinical support for clinicians treating patients with substance use disorder and serving as a vocal advocate for treatment, Jake has established himself as a key resource within the field. He has spoken at well over 100 pharmacy, nursing, and medical schools across the country in the past 5 years, sharing his story with students and faculty, and he regularly facilitates patient and parent support groups. Jake has recently established his own education and a clinical consulting group called Strategic Recovery Resources of which he is owner and CEO. He is also currently employed by Pear Therapeutics as a medical science liaison. Jake received his Doctor of Pharmacy Degree from the Massachusetts College of Pharmacy in 2000 and his Master’s Degree in Business Administration from UMass Boston in 2007.

Featured Speakers

Douglas Throckmorton, MD

Douglas Throckmorton, MD

Deputy Center Director of Regulatory Programs

U.S. Food and Drug Administration (FDA)
Deena Speights-Napata, MA

Deena Speights-Napata, MA

Executive Director

Maryland Board of Pharmacy
Maryland Department of Health
Robin Monson-Dupuis, LCSW, SAC, RYT

Robin Monson-Dupuis, LCSW, SAC, RYT

Director, Aurora Behavioral Health Services

Aurora Medical Group
Karin A. Mack, PhD

Karin A. Mack, PhD

Associate Director for Science, Division of Analysis, Research and Practice Integration, National Center for Injury Prevention and Control

Centers for Disease Control and Prevention (CDC)
Joe Guarisco, MD, FAAEM, FACEP

Joe Guarisco, MD, FAAEM, FACEP

System Chair Emergency Services, Academic Chair Department of Emergency Medicine

Ochsner Health System
Jeff Beeson

Jeff Beeson

Deputy Director

Washington/Baltimore High Intensity Drug Trafficking Areas
Andrew Funk, PharmD

Andrew Funk, PharmD

Executive Director

Iowa Board of Pharmacy
Erika L. Marshall

Erika L. Marshall

Program Outreach Director

E-FORCSE Florida Prescription Drug Monitoring Program
Cody Wiberg, PharmD, MS, RPh

Cody Wiberg, PharmD, MS, RPh

Executive Director

Minnesota Board of Pharmacy
Alan McGill

Alan McGill

Supervisory Narcotics Agent

Pennsylvania Office of Attorney General
Bureau of Narcotics Investigation and Drug Control
Jody Gembarski, PharmD

Jody Gembarski, PharmD

Clinical Manager, Pharmacy Services, Clinical Quality Programs and Controlled Substances

Blue Cross Blue Shield of Michigan and Blue Care Network
Susan Hawk, MS, PCC-S, LSW, CGP

Susan Hawk, MS, PCC-S, LSW, CGP

Chief Clinical Integration Behavioral Health

Mercy Health
Director of Operations Behavioral Health
St. Rita’s Health Partners
Jordan Barbour, MPH

Jordan Barbour, MPH

Director of Clinical Operations, Psychiatry and Addiction Medicine

Geisinger Health
Scott Weiner, MD

Scott Weiner, MD

Attending Emergency Physician, Director, Brigham Comprehensive Opioid Response and Education (B-CORE) Program

Brigham and Women’s Hospital
Kim Gaedeke

Kim Gaedeke

Acting Deputy Director, Department of Licensing and Regulatory Affairs

State of Michigan
Brad Bauer

Brad Bauer

Senior Vice President, Business Development

Appriss Health
Jake Nichols, PharmD, MBA

Jake Nichols, PharmD, MBA

Chief Executive Officer

Strategic Recovery Resources, LLC
Brian Caveney, M.D.

Brian Caveney, M.D.

Chief Medical Officer

LabCorp
Venue

Omni Shoreham Hotel
2500 Calvert Street NW
Washington, DC 20008
202-234-0700

Mention BRI Network to get the discounted rate of $209/night

Sponsors and Exhibitors

Lead Sponsor

 
Daiichi-SankyoDaiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd. Daiichi Sankyo, Inc. is a member of the Daiichi Sankyo Group and is focused on the development of oncology therapies and specialty medicines. Daiichi Sankyo, Inc. medicines approved in the U.S. include therapies for hypertension, pain management, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.

 

 

Executive Sponsors

 
Appriss Health provides the nation’s most comprehensive platform for early identification, prevention, and management of SUD. We provide state government agencies with the most advanced repository of controlled substance dispensing data and deliver real-time clinical decision support, critical insights, and interventions to physicians, pharmacists, and care team members. Our solutions help prescribers and dispensers assess and manage clinical risk by providing access to critical information at the point of care for hundreds of millions of patient encounters each year. Appriss Health provides the platform for PDMPs and access to non-PDMP data, analytics, tools, and resources from PDMPs, across state lines, and integrated within care team workflows. Sharing #knowledgeforgood, our solutions are improving patient safety and outcomes. For more information, please visit www.apprisshealth.com.
 
LabCorp and MedTox – Empower Change | Address the Opioid Crisis – Together we offer options that provide unparalleled clinical value for monitoring patients who are prescribed controlled substances. LabCorp provides choice in test options to meet individual patient needs including: customizable drug test options, broad-spectrum profile offerings, and medication assisted treatment test options. In addition, LabCorp’s collaboration with The Recovery Platform provides a valuable monitoring tool to help physicians address and manage the ongoing opioid crisis. LabCorp also offers an extensive managed care network and a comprehensive menu of diagnostic and preventive tests, including infectious disease testing that may be appropriate for opioid use disorder patients. For information or to set up a testing program, contact us at 800-832-3244 or MedWatch-mtx
 

Exhibitor

 
BioCorRx Recovery ProgramBioCorRx® Recovery Program is a comprehensive two-part outpatient, “non-addictive” medication-assisted treatment (MAT) protocol for alcohol and opioid addictions. Consisting of naltrexone implant and Cognitive behavioral therapy (CBT) based, solution oriented counseling module, plus 12 months of remote Recovery Support Specialist (RSS) care. This cutting-edge, proven and effective treatment modality is available to consumers via authorized independent practitioners and is designed to blend within the framework of one’s everyday life.

The Comprehensive BioCorRx® recovery program blends aggressive medical management in the form of a minimally invasive procedure, involving the subcutaneous insertion of specially compounded implants (pellets) which contain the FDA approved medication naltrexone, combined with a proprietary CBT program and peer support specific to the naltrexone treatment.
 

ADAPT Pharma® is a privately-held company committed to expanding affordable access to NARCAN® (naloxone HCI) Nasal Spray and to developing new treatment options in the field of opioid overdose and addiction. Our mission is to provide simple, reliable, and accessible therapeutic options, ensuring that patients, and those who care for them, have access to the right treatment at the right time.
 

Media Partner

 
Managed Care delivers high-interest articles and features developed through original research and writing. Its editorial mission is to advise managed markets physicians, pharmacists, and executives on the integration of the business and medical aspects of the rapidly changing managed care market. A strict fact-checking and peer-review process assures the accuracy and relevance of editorial content.
 
PCSS is a program funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) created in response to the opioid overdose epidemic to train primary care providers in the evidence-based prevention and treatment of opioid use disorders (OUD) and treatment of chronic pain. The project is geared toward primary care providers who wish to treat OUD. PCSS is made up of a coalition, led by American Academy of Addiction Psychiatry, of major healthcare organizations all dedicated to addressing this healthcare crisis. Through a variety of trainings and a clinical mentoring program, PCSS’s mission is to increase healthcare providers’ knowledge and skills in the prevention, identification, and treatment of substance use disorders with a focus on opioid use disorders.

FAQ

Are there group discounts available?

  • Yes – Register a group of 3 or more at the same time and receive an additional 10% off the registration fee

Are there discounts for Non-Profit/Government Organizations?

  • Yes – please call us at 800-743-8490 for special pricing

What is the cancellation policy?

  • Cancellations received 3 weeks prior to the event will receive a refund minus the administration fee of $185. Cancellation received less than 3 weeks prior to the event will receive a credit to a future event valid for one year.

Can the registration be transferred to a colleague?

  • Yes – please email us in writing at info@brinetwork.com with the colleague’s name and title

Where can I find information on the venue/accommodations?

  • Along with your registration receipt you will receive information on how to make your hotel reservations. You can also visit individual event page for specific hotel information. The conference fee does not include the cost of accommodations.

What is the suggested dress code?

  • Business casual. Meeting rooms can sometimes be cold so we recommend a sweater or light jacket
Request Brochure

Register Your Team Today!

Register Now
Ask A Question

Be A Thought Leader And Share!

Pin It on Pinterest